---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-132710"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T03:14:04.703179+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xilio reports 26% ORR for vilastobart+atezo in MSS CRC without liver mets; plans to partner program

## Summary
- 26% ORR (7 PRs, 6 confirmed) in 27 MSS CRC patients without liver metastases; responses ongoing up to 37 weeks.
- Differentiated safety: only 7% colitis (3/44), low discontinuation (5%); combination well-tolerated.
- Patient with liver metastasis from Phase 1C on treatment >14 months; 150mg Q6W dose cleared and cohort enrolling.
- Xilio seeking partnership for vilastobart to accelerate development; additional data expected H1 2026.

## SEC filing metadata
- accession: 0001193125-25-132710
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000119312525132710/0001193125-25-132710-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000119312525132710/d91295d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-132710
- JSON: https://secwatch.observer/filing/0001193125-25-132710.json
- Plain text: https://secwatch.observer/filing/0001193125-25-132710.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.